Matrix M adjuvant technology

Novel Immune Potentiators and Delivery Technologies for Next Generation Vaccines

Volumn , Issue , 2013, Pages 309-320

  Bengtsson, Karin Lövgren ^a  

^a CSO Isconova AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84929546451     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-5380-2_15     Document Type: Chapter

References (41)

1. Brunner R, Jensen-Jarolim E, Pali-Schöll I (2010) The ABC of clinical and experimental adjuvants- a brief overview. Immunol Lett 128:29-35
2. Bachmann MF, Jennings GT (2010) Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 10:787-796
3. Cox J, Coulter A (1997) Adjuvants-A classification and review of their modes of action. Vaccine 15:248-256
4. Rajput ZI, Hu S, Xiao C, Arijo AG (2007) Adjuvant effects of saponins on animal immune responses. J Zhejiang Univ Sci B 8:153-161
5. Francis G, Kerem Z, Makkar HP, Becker K (2002) The biological action of saponins in animal systems: a review. Br J Nutr 88:587-605
6. Kensil CR (1996) Saponins as vaccine adjuvants. Crit Rev Ther Drug Carrier Syst 13:1-55
7. Waite DC, Jacobson EW, Ennis FA, Edelman R, White B, Kammer R, Anderson C, Kensil CR (2001) Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine 19:3957-3967
8. Morein B, Sundquist B, Höglund S, Dalsgaard K, Osterhaus A (1984) Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 308:457-460
9. Morein B, Sharp M, Sundquist B, Simons K (1983) Protein subunit vaccines of parainfluenza type 3 virus: immunogenic effect in lambs and mice. J Gen Virol 64:1557-1569
10. Özel M, Höglund S, Gelderblom H, Morein B (1989) Quarternary structure of the innubénostimulating complex (ISCOM). J Ultrastruct Mol Struct Res 102:240-248
11. Barr IG, Mitchell GF (1996) ISCOMs (immunostimulating complexes): thefirst decade. Immunol Cell Biol 74:8-25
12. Morein B, Lövgren-Bengtsson K (1998) Functional aspects of ISCOMs. Immunol Cell Biol 176:295-299
13. Morein B, Lövgren-Bengtsson K (1999) Immunomodulation by ISCOMs. In: Boraschi D, Tagliabue A (eds) A companion to methods in enzymology. Developments in adjuvant technology. Methods 19:94-102
14. Sanders MT, Brown LE, Deliyannis G, Pearse MJ (2005) ISCOM-based vaccines: the second decade. Immunol Cell Biol 83:119-128
15. Jones PD, Tha Hla R, Morein B, Lövgren K, Ada GL (1988) Cellular immune responses in the murine lung to local immunization with influenza a virus glycoproteins in micelles and immunostimulating complexes (ISCOMs). Scand J Immunol 27:645-652
16. Takahashi H, Takeshita T, Morein B, Putney S, Germain RN, Berzofsky J (1990) Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope proteins in ISCOMs. Nature 344:873-875
17. Wood JM (2001) Developing vaccines against pandemic influenza. Philos Trans R Soc Lond Biol Sci 356:1953-1960
18. Daems R, Del Giudice G, Rappuoli R (2005) Anticipating crisis: towards a pandemicflu vaccination strategy through alignment of public health and industrial policy. Vaccine 23:5732-5742
19. Lövgren K, Morein B (1991) The ISCOM: an antigen delivery system with built-in adjuvant. Mol Immunol 28:285-286
20. Fossum C, Bergström M, Lövgren K, Watson DL, Morein B (1990) Effect of iscom and/or their adjuvant moiety (matrix) on the initial proliferative and il-2 responses in vitro. Comparison of spleen cells from mice inoculated with ISCOMs and/or matrix. Cell Immunol 129:414-425
21. Lövgren K, Morein B (1988) The requirement of lipids for the formation of immunostimulating complexes (ISCOMs). Biotechnol Appl Biochem 10:161-172
22. Weijer K, Pfauth A, van Herwijnen R, Jarrett O, Meloen RH, Tomee C, Osterhaus AD (1993) Induction of feline leukaemia virus-neutralizing antibodies by immunization with synthetic peptides derived from the FeLV env gene. Vaccine 11:946-956
23. Voeten JT, Rimmelzwaan GF, Nieuwkoop NJ, Lövgren-Bengtsson K, Osterhaus AD (2000) Introduction of the haemagglutinin transmembrane region in the influenza virus matrix protein facilitates its incorporation into ISCOM and activation of specific CD8(+) cytotoxic T lymphocytes. Vaccine 19:514-522
24. Oyewumi MO, Kumar A, Cui Z (2010) Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines 9:1095-1107
25. Chen HC, Sun B, Tran KK, Shen H (2011) Effects of particle size on toll-like receptor 9-mediated cytokine profiles. Biomaterials 32:1731-1737
26. Lövgren Bengtsson K, Sjölander A (1996) Adjuvant activities of ISCOMs and ISCOM matrix; two different formulations of Quillaja saponin and antigen. Vaccine 14:753-760
27. Madhun AS, Haaheim LR, Nilsen MV, Cox RJ (2009) Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice. Vaccine 27:7367-7376
28. Cox RJ, Pedersen G, Madhun AS, Svindland S, Sævik M, Breakwell L et al (2011) Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial. Vaccine 29:8049-8059
29. Pedersen G, Major D, Roseby S, Wood J, Madhun AS, Cox RJ (2011) Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model. Influenza Other Respi Viruses 5:426-437
30. Sjölander A, Lövgren Bengtsson K, Morein B (1997) Kinetics, localization and cytokine profile of T cell responses to immune stimulating complexes (ISCOMs) containing human influenza virus envelope glycoproteins. Vaccine 15:1030-1038
31. Paillot R, Grimmett H, Elton D, Daly JM (2004) Protection, systemic IFNgamma, and antibody responses induced by an ISCOM-based vaccine against a recent equine influenza virus in its natural host. Vet Res 39:21
32. Crouch CF, Daly J, Hannant D, Wilkins J, Francis MJ (2004) Immune responses and protective efficacy in ponies immunised with an equine influenza ISCOM vaccine containing an 'American lineage' H3N8 virus. Vaccine 23:418-425
33. Heldens JG, Pouwels HG, Derks CG, Van de Zande SM, Hoeijmakers MJ (2009) Thefirst safe inactivated equine influenza vaccine formulation adjuvanted with ISCOM-Matrix that closes the immunity gap. Vaccine 27:5530-5537
34. Heldens JG, Pouwels HG, Derks CG, Van de Zande SM, Hoeijmakers MJ (2010) Duration of immunity induced by an equine influenza and tetanus combination vaccine formulation adjuvanted with ISCOM-Matrix. Vaccine 28:6989-6996
35. Kamstrup S, San Martin R, Doberti A, Grande H, Dalsgaard K (2000) Preparation and characterisation of quillaja saponin with less heterogeneity than Quil-a. Vaccine 18:2244-2249
36. Cox JC, Sjölander A, Barr IG (1998) ISCOMs and other saponin based adjuvants. Adv Drug Deliv Rev 32:247-271
37. Johansson M, Lövgren-Bengtsson K (1999) ISCOMs with different quillaja saponin components differ in their immunomodulating activities. Vaccine 17:2894-2900
38. Lövgren Bengtsson K, Morein B, Osterhaus AD (2011) ISCOM technology-based Matrix M™ adjuvant: success in future vaccines relies on formulation. Expert Rev Vaccines 10:401-403
39. Eyles JE, Hartley MG, Laws TR, Oyston PC, Griffin KF, Titball RW (2008) Protection afforded against aerosol challenge by systemic immunisation with inactivated Francisella tularensis live vaccine strain (LVS). Microb Pathog 44:164-168
40. Douagi I, Forsell MN, Sundling C, O'Dell S, Feng Y, Dosenovic P et al (2010) Influence of novel CD4 binding-defective HIV-1 envelope glycoprotein immunogens on neutralizing antibody and T-cell responses in nonhuman primates. J Virol 84:1683-1695
41. Dasari V, Smith C, Zhong J, Scott G, Rawlinson W, Khanna R (2011) Recombinant glycoprotein B vaccine formulation with toll-like receptor 9 agonist and immune-stimulating complex induces specific immunity against multiple strains of cytomegalovirus. J Gen Virol 92:1021-1031